LOXO-292
99%
- Product Code: 101280
CAS:
2222755-14-6
| Molecular Weight: | 553.61 g./mol | Molecular Formula: | C₂₉H₃₁N₉O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
LOXO-292, also known as Selpercatinib, is primarily used in the treatment of certain types of cancer that are driven by specific genetic alterations. It is particularly effective in targeting cancers with RET gene mutations or fusions, which are often found in non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers. By inhibiting the RET protein, LOXO-292 helps to block the signaling pathways that promote cancer cell growth and survival. This targeted therapy offers a more precise approach compared to traditional chemotherapy, often resulting in fewer side effects and improved outcomes for patients with RET-altered cancers. It is typically administered orally, making it convenient for long-term treatment regimens. Clinical trials have demonstrated its efficacy in shrinking tumors and improving progression-free survival in patients with advanced or metastatic RET-driven cancers.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White Solid |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿9,500.00 |
+
-
|
| 0.250 | 10-20 days | ฿19,990.00 |
+
-
|
LOXO-292
LOXO-292, also known as Selpercatinib, is primarily used in the treatment of certain types of cancer that are driven by specific genetic alterations. It is particularly effective in targeting cancers with RET gene mutations or fusions, which are often found in non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers. By inhibiting the RET protein, LOXO-292 helps to block the signaling pathways that promote cancer cell growth and survival. This targeted therapy offers a more precise approach compared to traditional chemotherapy, often resulting in fewer side effects and improved outcomes for patients with RET-altered cancers. It is typically administered orally, making it convenient for long-term treatment regimens. Clinical trials have demonstrated its efficacy in shrinking tumors and improving progression-free survival in patients with advanced or metastatic RET-driven cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :